GSK Leans on U.S. Legal Expertise for $2 Billion Acquisition Deal with Boston Pharmaceuticals

Pieter Gunst01 mins

GlaxoSmithKline (GSK), the renowned pharmaceutical company listed in the UK, has once again opted for a U.S. law firm to handle a significant transaction. Cleary Gottlieb Steen & Hamilton has been engaged to advise GSK on its agreement to acquire a liver disease drug from Boston Pharmaceuticals. The transaction, totaling up to $2 billion, features an initial payment of $1.2 billion for the late-stage trial medication, efimosfermin. This move showcases GSK’s ongoing reliance on U.S. legal expertise for its transactional needs as highlighted in their confirmation on the London Stock Exchange on Wednesday.